RecruitMe Clinical Trial

A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous System Tumors That are Amenable to Direct Injection
A study for children and adolescents with advanced non central nervous system (CNS) tumors using study drug Talimogene laherparepvec
Sponsor:Amgen Inc.
Enrolling:Male and Female Patients
Age Range:Between 2 and 21 years old
IRB Number:AAAQ6917
U.S. Government ID:NCT02756845
Contact: Stergios Zacharoulis, MD: 212-305-7212 / sz2764@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find out more about how the study drug called talimogene laherparepvec will be used in children/adolescents/young adults with advanced solid tumors not involving the central nervous system that are available for direct injection. This is a phase 1 study, multicenter, open-label study, that means all subject enrolled in the study will be assigned talimogene laherparepvec. The study drug is a genetically modified virus. The virus' genes were modified in a laboratory to make the virus active in the tumor cell but not in normal cell. Talimogene laherparepvec is given as a direct injection into the tumors with a needle. Male or female subjects aged 2 to 21 years will be enrolled into 2 cohorts stratified by age.

Do You Qualify?
Has your child been diagnosed with Non-CNS Tumors?YesNo
Submit
Cancel
Investigator
Stergios Zacharoulis, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Stergios Zacharoulis, MD
Email: sz2764@cumc.columbia.edu
Phone: 212-305-7212